Salamanca City Central School District on Seneca Nation Reservation to Deploy Optio and Realbotix M-Series Humanoid Robot; Pilot to Expand to Approximately 500 High School Students in Fall 2026; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp. CINCINNATI, Ohio, June 24, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC (“Realbotix”), the target of Onconetix’s previously announced pending acquisition. Realbotix has launched Optio, its AI-powered teacher’s assistant, in a pilot program at Salamanca City Central School District, located on the Seneca Nation Reservation in New York. As part of the initiative, the district is also deploying a Realbotix M-Series humanoid robot to enhance interactive classroom engagement. Optio is Realbotix’s AI-powered teacher’s assistant and at-home tutor, designed to extend learning beyond school hours. Students interact with personalized avatars trained in district curriculum, delivering educationally regulated support, concept reinforcement, individual tutoring, and 24/7 homework support across multiple languages. The platform is designed to support both students and educators and includes education-specific safety guardrails, protections against inappropriate responses, and operates under full district oversight. Optio is also designed to support neurodiverse learners through personalized, always-available reinforcement. Salamanca City Central School District is a recognized Woz ED STEM Pathway district. The initial Optio deployment will support high school students in Woz ED AI and Robotics courses. The pilot program will also deploy a Realbotix M-Series humanoid robot, which uses natural conversation, facial expressions, and real-time interaction to create hands-on learning experiences in the classroom. As previously announced on February 12, 2026, Onconetix entered into a definitive share exchange agreement to acquire 100% of the issued and outstanding equity interests of Realbotix LLC, a wholly-owned subsidiary of Realbotix Corp., in an all-stock transaction. The combined company is expected to trade on Nasdaq following closing, which is anticipated to occur in the second half of 2026, subject to Onconetix shareholder approval, required regulatory approvals, and other closing conditions. This communication includes information regarding Realbotix, a company that Onconetix has agreed to acquire, and is being provided for informational purposes only. Investors are cautioned not to place undue reliance on forward-looking or projected information. About Onconetix, Inc. Onconetix, Inc. (Nasdaq: ONCO) is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative oncology solutions. Onconetix owns Proclarix®, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union under the IVDR, which it anticipates will be marketed in the U.S. as a lab developed test through its license agreement with Labcorp. For more information, visit www.onconetix.com . About Realbotix LLC Realbotix LLC is a wholly-owned subsidiary of Realbotix Corp. (TSX-V: XBOT; Frankfurt: 76M0.F; OTC: XBOTF) and the target of Onconetix’s pending acquisition. Realbotix LLC develops AI-powered humanoid robots designed for human interaction across enterprise and consumer environments. Manufactured in the United States, Realbotix’s patented AI and robotics technologies enable lifelike expressions, motion, vision, and social engagement. For more information, visit www.realbotix.ai . Additional Information and Where to Find It In connection with the proposed transaction between Realbotix and Onconetix, Onconetix intends to file with the SEC a Registration Statement on Form S-4 (the “Registration Statement”) to register the common stock to be issued by Onconetix in connection with the proposed transaction. The Registration Statement will include a proxy statement of Onconetix and a prospectus of Onconetix (the “Proxy Statement/Prospectus”), and each of Realbotix and Onconetix may file with the SEC other relevant documents concerning the proposed transaction. After the Registration Statement is declared effective, the definitive Proxy Statement/Prospectus will be sent to the stockholders of Onconetix to seek their approval of the proposed transaction. This is not a substitute for the Registration Statement, the Proxy Statement/Prospectus or any other relevant documents that Realbotix or Onconetix has filed or will file with the SEC. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND STOCKHOLDERS OF ONCONETIX ARE URGED TO CAREFULLY AND ENTIRELY READ THE REGISTRATION STATEMENT AND PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION AND ANY OTHER RELEVANT DOCUMENTS, AS WELL AS ANY